We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Hand-Held Lab-On-A-Chip Diagnoses HIV

By LabMedica International staff writers
Posted on 09 Aug 2011
A hand-held lab-on-a-chip diagnoses infectious diseases such as Human immunosuppressive virus (HIV) and syphilis at patients' bedsides.

Named the mChip (from mobile microfluidic chip), the integrated microfluidic-based diagnostic device—a lab-on-a-chip—can perform complex laboratory assays, and do so with such simplicity that these tests can be carried out in the most remote regions of the world.

Prof. More...
Samuel K. Sia's lab at Columbia Engineering (New York, NY, USA) developed the mChip devices in collaboration with Claros Diagnostics Inc. (Woburn, MA, USA), a venture capital-backed startup that Sia cofounded in 2004. The cost of the chip is about US$1 and the entire instrument about $100.

In a paper published online in Nature Medicine on July 31, 2011, Prof. Sia and his colleagues presented field results on how microfluidics and nanoparticles could be successfully leveraged to produce a functional low-cost diagnostic device in extreme resource-limited settings. The authors wrote, "The chip had excellent performance in the diagnosis of HIV using only 1 μL of unprocessed whole blood and an ability to simultaneously diagnose HIV and syphilis with sensitivities and specificities that rival those of reference benchtop assays"

Prof. Sia and his team performed the testing in Rwanda during four years in partnership with Columbia's Mailman School of Public Health (New York, NY, USA) and three local nongovernmental organizations in Rwanda, targeting hundreds of patients.

"We have engineered a disposable credit card-sized device that can produce blood-based diagnostic results in minutes," said Prof. Sia. "The idea is to make a large class of diagnostic tests accessible to patients in any setting in the world, rather than forcing them to go to a clinic to draw blood and then wait days for their results."

The device allows blood checks for deadly infectious diseases that could benefit newborns and pregnant women especially in pockets where diagnostic tests are either not possible or not reachable. Results can be seen with the naked eye or with a low-cost detector.

Named one of the world's top young innovators for 2010 by MIT's Technology Review for his work in biotechnology and medicine, and by NASA as one of 10 innovators in human health and sustainability, Prof. Sia also received a Career award in 2008 from the National Science Foundation.

Related Links:
Columbia Engineering
Claros Diagnostics Inc.
Columbia's Mailman School of Public Health




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.